Antibody and viral RNA kinetics in SARS-CoV2 infected patients admitted to a Romanian University Hospital of Infectious Diseases.
COVID-19
SARS-CoV-2
Viral kinetics
antibody profile
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
10
03
2021
revised:
20
04
2021
accepted:
20
04
2021
pubmed:
27
4
2021
medline:
3
7
2021
entrez:
26
4
2021
Statut:
ppublish
Résumé
To assess the antibody and viral kinetics in asymptomatic/mild confirmed SARS-CoV-2 infections compared to more severe patients. Retrospective analysis of data obtained from adult patients with a confirmed SARS-CoV2 infection having at least one SARS-CoV-2 pair of specific IgM/IgG tests, admitted in The University Hospital of Infectious Diseases Cluj-Napoca, Romania (28 February to 31 August 2020). The database also included: demographic, clinical, chest X-ray and/or CT scan results, RT-PCR SARS-CoV-2, and dexamethasone treatment. A total of 469 patients were evaluated as "asymptomatic/mild" and "moderate/severe/critical" cases. The median time since confirmation to SARS-CoV-2 PCR negativity was 15 days [95% CI: 13-18] in asymptomatic/mild cases and 17 days [95% CI: 16-21] in moderate/severe ones. The median time to seroconversion for both IgM and IgG was 13 days [95% CI: 13-14] in asymptomatic/mild cases and 11 days [95% CI: 10-13] in moderate/severe ones. For both antibody types, the highest reactivity was significantly associated with more severe presentation (IgM: OR = 10.30, IgG: OR = 7.97). Asymptomatic/mild COVID-19 cases had a faster RT-PCR negativity rate compared to moderate/severe/critical patients. IgG and IgM dynamics were almost simultaneous, more robust for IgG in more severe cases, and at one month after confirmation, almost all patients had detectable antibody titers.
Identifiants
pubmed: 33901653
pii: S1201-9712(21)00379-9
doi: 10.1016/j.ijid.2021.04.067
pmc: PMC8064896
pii:
doi:
Substances chimiques
Antibodies, Viral
0
RNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
205-211Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
Références
J Clin Virol. 2020 Sep;130:104542
pubmed: 32707511
Cochrane Database Syst Rev. 2020 Jun 25;6:CD013652
pubmed: 32584464
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
JAMA. 2020 Oct 6;324(13):1279-1281
pubmed: 32915201
Nat Microbiol. 2020 Dec;5(12):1598-1607
pubmed: 33106674
Immunity. 2020 Nov 17;53(5):925-933.e4
pubmed: 33129373
Emerg Microbes Infect. 2020 Dec;9(1):2200-2211
pubmed: 32962560
Science. 2020 Sep 4;369(6508):
pubmed: 32669297
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Clin Microbiol Infect. 2020 Nov;26(11):1557.e1-1557.e7
pubmed: 32745595
Science. 2020 Dec 11;370(6522):1339-1343
pubmed: 33159009
Nat Med. 2020 Dec;26(12):1919-1928
pubmed: 33057181
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
J Infect. 2021 Mar;82(3):414-451
pubmed: 33115658
J Infect. 2020 Jul;81(1):e13-e20
pubmed: 32283144
Clin Infect Dis. 2020 Apr 27;:
pubmed: 32338708
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
J Clin Virol. 2020 Sep;130:104583
pubmed: 32791382
Cochrane Database Syst Rev. 2020 Sep 30;9:CD013639
pubmed: 32997361
Immunity. 2020 Sep 15;53(3):524-532.e4
pubmed: 32783920
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Clin Radiol. 2020 Nov;75(11):876.e33-876.e39
pubmed: 32861461
Lancet. 2021 Apr 17;397(10283):1459-1469
pubmed: 33844963
Crit Care. 2021 Jan 4;25(1):2
pubmed: 33397463
Science. 2020 Dec 4;370(6521):1227-1230
pubmed: 33115920
Nat Med. 2020 Oct;26(10):1623-1635
pubmed: 32807934
Lancet Infect Dis. 2020 Aug;20(8):e192-e197
pubmed: 32539990
BMJ. 2020 Sep 8;370:m3325
pubmed: 32900692
Nat Rev Immunol. 2020 Jun;20(6):339-341
pubmed: 32317716
N Engl J Med. 2021 Apr 8;384(14):1372-1374
pubmed: 33691060
JAMA Intern Med. 2020 Nov 1;180(11):1447-1452
pubmed: 32780793
Lancet. 2021 Mar 27;397(10280):1204-1212
pubmed: 33743221
JAMA. 2020 Jun 9;323(22):2249-2251
pubmed: 32374370
Int Immunopharmacol. 2020 Sep;86:106746
pubmed: 32619956